EXPLORE!

Rates of Antimicrobial Resistance in Helicobacter pylori Isolates from Clinical Trial Patients Across the US and Europe

  831 Views

#Gastroenterology 

eMediNexus    09 November 2022

For Helicobacter pylori infections, proton pump inhibitor (PPI)-based triple regimens with clarithromycin are not recommended in areas where clarithromycin resistance is more than 15% or in patients who have previously taken macrolides. Up-to-date information on local resistance patterns is scarce, especially in the US. The present study reports resistance rates to antibiotics commonly used to treat H. pylori from a large study conducted in the US and Europe (pHalcon-HP).

 

The study collected Gastric mucosal biopsies from adult participants with H. pylori infection during screening. It determined Minimum inhibitory concentrations via agar dilution for clarithromycin, amoxicillin, and metronidazole, with breakpoints ≥1 µg/mL, >0.125 µg/mL, and >8 µg/mL, respectively. It obtained resistance rates for the US and Europe and also for US subregions and participating European countries.

 

The study observed-

 

  • It established Resistance rates in isolates from 907 participants.
  • 22.2% were resistant to clarithromycin, 1.2% to amoxicillin, and 69.2% to metronidazole.
  • Similar Resistance in the US and Europe
  • The most prevalent resistance was from metronidazole (50-79%), while the least was from amoxicillin (≤5%).
  • All subregions, except the UK, showed resistance to clarithromycin in ≥15% of isolates.
  • Among clarithromycin-resistant isolates, 75% were also metronidazole-resistant.
  • Among two US isolates resistant to clarithromycin and amoxicillin, one was also metronidazole-resistant.

 

This study shows the resistance rates that disfavor the continued empiric use of PPI-based triple therapy containing clarithromycin, per treatment guidelines, and highlights the need for antibiotic resistance surveillance and novel treatment strategies for H. pylori infection in the US and Europe.

 

Am J Gastroenterol. 2022 Sep 30. doi: 10.14309/ajg.0000000000002045. Epub ahead of print. PMID: 36191284.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.